Link Pharma Chem Ltd.

BSE: 524748 SECTOR: Pharmaceuticals & Drugs  6106   28   2

39.64
-1.66 (-4.02%)
BSE: 26 May 05:10 PM

Price Summary

Today's High

₹ 41.38

Today's Low

₹ 39

52 Week High

₹ 75

52 Week Low

₹ 0

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17.6 Cr.

Enterprise Value

23.11 Cr.

No. of Shares

0.44 Cr.

P/E

15.66

P/B

1.15

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  34.55

CASH

0.88 Cr.

DEBT

6.39 Cr.

Promoter Holding

51.49 %

EPS (TTM)

₹  2.53

Sales Growth

53.85%

ROE

13.92 %

ROCE

16.57%

Profit Growth

73.46 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year53.85%
3 Year29.79%
5 Year27.17%

Profit Growth

1 Year73.46%
3 Year41.93%
5 Year52.71%

ROE%

1 Year13.92%
3 Year10.56%
5 Year10.11%

ROCE %

1 Year16.57%
3 Year14.34%
5 Year13.74%

Debt/Equity

0.4413

Price to Cash Flow

-14.07

Interest Cover Ratio

6.81028368794326

CFO/PAT (5 Yr. Avg.)

2.04913243001183

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 51.49 0
Dec 2022 51.49 0
Sep 2022 51.49 0
Jun 2022 51.49 0
Mar 2022 51.49 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 29.7851211279633% for the Past 3 years.
  • Company’s PEG ratio is 0.21318322786512.
  • The company has an efficient Cash Conversion Cycle of 3.6972353124639 days.
  • The company has a high promoter holding of 51.49%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.55044922944369.

 Limitations

  • Company has negative cash flow from operations of -1.2511.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 14.03 11.29 11.63 8.47 9.36
Total Expenditure 12.99 10.64 10.78 7.53 8.72
Operating Profit 1.04 0.65 0.85 0.94 0.65
Other Income 0.32 -0.01 -0.81 0.61 0.08
Interest 0.16 0.04 0.17 0.14 0.19
Depreciation 0.22 0.27 0.23 0.23 0.24
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.99 0.33 -0.35 1.18 0.3
Tax 0.29 0.05 -0.06 0.22 0.12
Profit After Tax 0.7 0.28 -0.29 0.96 0.18
Adjusted EPS (Rs) 1.58 0.62 -0.66 2.17 0.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 23.53 24.5 25.47 34.81 53.56
Total Expenditure 20.76 22.48 22.87 31.85 50.36
Operating Profit 2.78 2.02 2.6 2.97 3.2
Other Income 0.07 0.19 0.13 0.03 0.8
Interest 0.62 0.39 0.36 0.44 0.45
Depreciation 0.86 0.89 0.93 0.87 0.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.37 0.93 1.44 1.68 2.62
Tax 0.24 0.27 0.49 0.59 0.74
Net Profit 1.13 0.66 0.95 1.08 1.88
Adjusted EPS (Rs.) 2.56 1.48 2.14 2.44 4.24

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 4.44 4.44 4.44 4.44 4.44
Total Reserves 5.35 5.94 6.99 8.12 10.03
Borrowings 2.25 1.71 3.17 3.16 2.9
Other N/C liabilities 0.79 1.04 0.91 1.04 0.98
Current liabilities 4.36 4.88 3.45 9.28 10.61
Total Liabilities 17.19 18 18.97 26.04 28.96
Assets
Net Block 9.76 9.14 8.81 8.71 8.79
Capital WIP 0.01 0.43 0 0 0.21
Intangible WIP 0 0 0 0 0
Investments 0.03 0.03 0.03 0.03 4.52
Loans & Advances 0.8 1.2 0.98 2.09 1.73
Other N/C Assets 0 0.02 0.07 0.07 0.15
Current Assets 6.58 7.18 9.08 15.14 13.58
Total Assets 17.19 18 18.97 26.04 28.96
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 1.37 0.93 1.44 1.68 2.62
Adjustment 1.47 1.26 2.04 1.46 0.93
Changes in Assets & Liabilities 1.25 -0.63 -0.64 2.18 -4.13
Tax Paid -0.3 -0.2 0.11 -0.48 -0.67
Operating Cash Flow 3.79 1.36 2.95 4.84 -1.25
Investing Cash Flow -1.15 -0.96 -1.66 -2.16 -4.98
Financing Cash Flow -2.63 -0.46 0.55 -0.33 2.27
Net Cash Flow 0 -0.05 1.85 2.35 -3.95

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 51.49 51.49 51.49 51.49 51.49
maya satish thakur 8.94 8.94 8.94 8.94 8.94
satish ganpatrao t... 14.91 14.91 14.91 14.89 14.80
rishikesh s thakur 0.60 0.60 0.60 0.60 0.60
balvant vinayak re... 13.47 13.47 13.47 13.17 13.09
neha balvant retar... 10.47 10.47 10.47 10.47 10.47
sonia satish thakur 0.33 0.33 0.33 0.33 0.33
shriniwas vasantra... 2.09 2.09 2.09 2.09 2.09
mayank balwant ret... 0.34 0.34 0.34 0.34 0.34
himanshu balwant r... 0.34 0.34 0.34 0.34 0.34
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 48.51 48.51 48.51 48.51 48.51
gurudev marketing ... 6.11 5.76 5.76 5.84 5.59
gurudev marketing ... - - - - -
gurudev marketing ... - - - - -
kotak daksha visha... 1.87 1.87 1.87 - -
daksha vishanji ko... - - - 1.86 1.86
girdharilal seksar... 1.12 1.12 1.12 1.14 1.14

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Link Pharma Chem Stock Price Analysis and Quick Research Report. Is Link Pharma Chem an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Link Pharma Chem and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -1.2511 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Link Pharma Chem has a Debt to Equity ratio of 0.4413 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Link Pharma Chem , the EPS growth was 73.461869090016 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Link Pharma Chem has OPM of 5.98312938988734 % which is a bad sign for profitability.
     
  • ROE: Link Pharma Chem have a average ROE of 13.9202675011282 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Link Pharma Chem

X